Advisor Resource Council Makes New $872,000 Investment in NeoGenomics, Inc. (NASDAQ:NEO)

Advisor Resource Council bought a new position in NeoGenomics, Inc. (NASDAQ:NEO - Free Report) in the first quarter, according to the company in its most recent disclosure with the SEC. The fund bought 96,343 shares of the medical research company's stock, valued at approximately $872,000. Advisor Resource Council owned 0.07% of NeoGenomics at the end of the most recent quarter.

Other large investors have also added to or reduced their stakes in the company. Swiss National Bank boosted its stake in shares of NeoGenomics by 1.0% during the 4th quarter. Swiss National Bank now owns 252,100 shares of the medical research company's stock worth $4,155,000 after acquiring an additional 2,600 shares during the last quarter. Rhumbline Advisers boosted its stake in shares of NeoGenomics by 2.4% during the 4th quarter. Rhumbline Advisers now owns 389,003 shares of the medical research company's stock worth $6,411,000 after acquiring an additional 9,098 shares during the last quarter. Charles Schwab Investment Management Inc. boosted its stake in shares of NeoGenomics by 2.4% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 1,161,352 shares of the medical research company's stock worth $19,139,000 after acquiring an additional 26,701 shares during the last quarter. GAMMA Investing LLC boosted its stake in shares of NeoGenomics by 1,107.7% during the 1st quarter. GAMMA Investing LLC now owns 17,765 shares of the medical research company's stock worth $1,872,000 after acquiring an additional 16,294 shares during the last quarter. Finally, KLP Kapitalforvaltning AS purchased a new position in shares of NeoGenomics during the 4th quarter worth $453,000. Institutional investors own 98.50% of the company's stock.

Analyst Upgrades and Downgrades

Several research analysts have recently weighed in on the stock. Morgan Stanley dropped their price target on shares of NeoGenomics from $17.00 to $10.00 and set an "equal weight" rating on the stock in a research note on Thursday, May 1st. Wall Street Zen upgraded shares of NeoGenomics from a "sell" rating to a "hold" rating in a research note on Tuesday, May 13th. Leerink Partners cut shares of NeoGenomics from an "outperform" rating to a "market perform" rating and lowered their target price for the company from $25.00 to $9.00 in a research note on Wednesday, April 30th. Guggenheim assumed coverage on shares of NeoGenomics in a research note on Thursday, May 15th. They set a "neutral" rating on the stock. Finally, Needham & Company LLC lowered their target price on shares of NeoGenomics from $18.00 to $8.50 and set a "buy" rating on the stock in a research note on Tuesday, April 29th. Seven research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company's stock. According to MarketBeat, NeoGenomics has a consensus rating of "Hold" and a consensus price target of $13.83.

Insider Transactions at NeoGenomics

In other news, CFO Jeffrey Scott Sherman purchased 20,000 shares of the business's stock in a transaction that occurred on Friday, May 2nd. The shares were bought at an average cost of $7.51 per share, for a total transaction of $150,200.00. Following the acquisition, the chief financial officer now owns 158,494 shares of the company's stock, valued at approximately $1,190,289.94. This trade represents a 14.44% increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director Michael Aaron Kelly purchased 5,000 shares of the business's stock in a transaction that occurred on Tuesday, May 27th. The shares were purchased at an average price of $7.60 per share, for a total transaction of $38,000.00. Following the completion of the acquisition, the director now directly owns 5,000 shares in the company, valued at $38,000. The trade was a ∞ increase in their position. The disclosure for this purchase can be found here. Insiders have acquired a total of 70,600 shares of company stock worth $550,438 in the last three months. Insiders own 2.40% of the company's stock.

NeoGenomics Stock Up 0.7%

Shares of NEO stock opened at $7.00 on Friday. The stock has a market cap of $900.90 million, a P/E ratio of -11.48 and a beta of 1.65. NeoGenomics, Inc. has a 52 week low of $6.08 and a 52 week high of $19.12. The company has a quick ratio of 1.95, a current ratio of 2.05 and a debt-to-equity ratio of 0.38. The company's fifty day simple moving average is $8.01 and its two-hundred day simple moving average is $11.39.

NeoGenomics (NASDAQ:NEO - Get Free Report) last announced its quarterly earnings results on Tuesday, April 29th. The medical research company reported ($0.08) EPS for the quarter, missing the consensus estimate of ($0.02) by ($0.06). NeoGenomics had a negative return on equity of 2.21% and a negative net margin of 11.54%. The company had revenue of $168.04 million during the quarter, compared to analysts' expectations of $171.38 million. During the same quarter in the previous year, the firm earned ($0.02) EPS. The firm's revenue for the quarter was up 7.6% compared to the same quarter last year. Analysts predict that NeoGenomics, Inc. will post -0.2 EPS for the current fiscal year.

NeoGenomics Company Profile

NeoGenomics, Inc operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. It operates through Clinical Services and Advanced Diagnostics segments. The company offers testing services to hospitals, academic centers, pathologists, oncologists, clinicians, pharmaceutical companies, and clinical laboratories.

Want to see what other hedge funds are holding NEO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for NeoGenomics, Inc. (NASDAQ:NEO - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.